Trastuzumab vedotin

Synonyms: MRG002; Trastuzumab MMAE
Trastuzumab vedotin (MRG002; Trastuzumab MMAE) 是一种靶向 HER2 的抗体药物偶联物和细胞毒素,与人源 HER2 的 Kd 为 0.075 nM,可结合 HER2 后发生内化和溶酶体转运,向表达 HER2 的细胞递送细胞毒性载荷,并在表达 HER2 的体内异种移植模型中诱导肿瘤消退,与抗 PD-1 抗体联合使用时抗肿瘤活性增强,对耐药的乳腺癌、胃癌和尿路上皮癌 PDX 模型表现出临床前抗肿瘤活性,其抗体依赖性细胞毒性活性低,可用于 HER2 阳性乳腺癌、HER2 阳性胃癌以及 HER2 阳性不可切除局部晚期或转移性尿路上皮癌的相关研究。
Trastuzumab vedotin
产品编号: MS-J10424 纯度: 98.05% 分子量: 150626 (average)
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
1mg
询价
3-5 天
5mg
询价
询价
10mg
询价
询价
25mg
询价
询价
50mg
询价
询价
100mg
询价
询价

产品描述

Trastuzumab vedotin (MRG002; Trastuzumab MMAE) 是一种靶向 HER2 的抗体药物偶联物和细胞毒素,与人源 HER2 的 Kd 为 0.075 nM,可结合 HER2 后发生内化和溶酶体转运,向表达 HER2 的细胞递送细胞毒性载荷,并在表达 HER2 的体内异种移植模型中诱导肿瘤消退,与抗 PD-1 抗体联合使用时抗肿瘤活性增强,对耐药的乳腺癌、胃癌和尿路上皮癌 PDX 模型表现出临床前抗肿瘤活性,其抗体依赖性细胞毒性活性低,可用于 HER2 阳性乳腺癌、HER2 阳性胃癌以及 HER2 阳性不可切除局部晚期或转移性尿路上皮癌的相关研究。

生物实验数据

生物活性 Trastuzumab vedotin (MRG002; Trastuzumab MMAE) is a HER2-targeting antibody-drug conjugate and cytotoxin with a Kd of 0.075 nM for human HER2 that, upon binding HER2, undergoes internalization and lysosomal trafficking to deliver a cytotoxic payload to HER2-expressing cells and induces tumor regression in HER2-expressing in vivo xenograft models, exhibits enhanced antitumor activity when combined with an anti-PD-1 antibody, shows preclinical antitumor activity in drug-resistant breast cancer, gastric cancer, and urothelial carcinoma PDX models, and has low antibody-dependent cellular cytotoxicity activity, making it suitable for research related to HER2-positive breast cancer, HER2-positive gastric cancer, and HER2-positive unresectable locally advanced or metastatic urothelial carcinoma.
体外研究
(In Vitro)

Trastuzumab vedotin (0.0128-1000 ng/mL;60 min; RT) 可选择性结合人和猴的 HER2 蛋白,未观察到与大鼠或小鼠 HER2 蛋白的结合。
Trastuzumab vedotin (4 μg/mL;30 min,37 °C) 在 37 °C 条件下可被 SKBR3 人乳腺癌细胞高效内化,其内化速率与其未偶联的抗体组分 MAB802 相当。
Trastuzumab vedotin (4 μg;4 h) 对 SKBR3 人乳腺癌细胞未表现出显著的 CDC 活性。

Cell Cytotoxicity Assay

Cell Line: SKBR3 (high HER2), BT-474 (high HER2), MDA-MB-453 (medium HER2) human breast cancer cell lines; NCI-N87 (high HER2) human gastric cancer cell line
Concentration: 0.02 ng/mL-200 μg/mL
Incubation Time: 96 ± 2 h
Result: Displayed potent sub-nanomolar cytotoxicity across all tested cell lines, with IC50 values of 0.012 nM (SKBR3), 0.035 nM (BT-474), 0.398 nM (MDA-MB-453), and 0.151 nM (NCI-N87). Its cytotoxicity was stronger than that of Kadcyla® in all high HER2-expressing cell lines tested.
体内研究
(In Vivo)

Trastuzumab vedotin (0.3-3 mg/kg;i.v.;每周 1 次;3 次) 在 BT-474 乳腺癌、NCI-N87 胃癌异种移植物模型中均表现出强效的、剂量依赖性抗肿瘤活性,在 3 mg/kg 剂量下观察到 BT-474 肿瘤生长被完全抑制。
Trastuzumab vedotin (1-10 mg/kg;静脉注射;每周 1 次;3 次) 在曲妥珠单抗 (MS-U55108) 耐药的 HER2 表达乳腺癌、胃癌 PDX 模型中表现出强效抗肿瘤活性。

Animal Model: BALB/c naked mice (immunodeficient)
Dosage: 0.3 mg/kg; 1 mg/kg; 3 mg/kg
Administration: i.v.; once weekly; 3 doses
Result: Significantly inhibited tumor growth at all tested doses.\nMaintained suppressed tumor volume relative to vehicle controls at 0.3 mg/kg.\nFurther reduced tumor growth at 1 mg/kg, with a relative tumor growth (T/C) value of 45%.\nMaintained tumor volume near baseline levels at 3 mg/kg, with a relative tumor growth (T/C) value of 0%, corresponding to strong antitumor activity (++++).
Animal Model: BALB/c naked mice (immunodeficient)
Dosage: 0.3 mg/kg; 1 mg/kg; 3 mg/kg
Administration: i.v.; once weekly; 3 doses
Result: Significantly inhibited tumor growth relative to vehicle controls at all tested doses.\nReduced tumor volume compared to vehicle at 0.3 mg/kg.\nStrongly suppressed tumor growth at 1 mg/kg.\nMaintained tumor volume near baseline levels at 3 mg/kg.
Animal Model: BALB/c naked mice (immunodeficient)
Dosage: 1 mg/kg (BC#046); 3 mg/kg (BC#046, BC#197, BC#239); 10 mg/kg (BC#197, BC#239)
Administration: i.v.; dosing schedule matching qw ×3 or equivalent
Result: In BC#046 model, reached a relative tumor growth (T/C) of 45% at 1 mg/kg (++ activity) and 0% at 3 mg/kg (++++ activity).\nIn BC#197 model, reached a relative tumor growth (T/C) of 14% at 3 mg/kg and 2% at 10 mg/kg (++++ activity at both doses).\nIn BC#239 model, reached a relative tumor growth (T/C) of 10% at 3 mg/kg and 3% at 10 mg/kg (++++ activity at both doses).\nShowed stronger antitumor activity than the reference drug at equivalent doses.
Animal Model: Hu-HSC-NPG humanized mice (NPG mice transplanted with human CD34+ hematopoietic stem cells)
Dosage: 3 mg/kg
Administration: i.v.; once every 3 weeks; 2 doses
Result: Significantly inhibited tumor growth relative to vehicle controls as a single agent.\nEnhanced antitumor activity when combined with an anti-PD-1 antibody (HX008), with a statistically significant difference (p < 0.05) observed on Day 21 compared to the target reagent alone.
性状 液体
颜色 Colorless to light yellow

化学信息

分子量 150626 (average)
别名 MRG002; Trastuzumab MMAE

储存&溶解度

储存方式

-80°C, protect from light

运输条件 Shipping with dry ice.

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础